Menu

CME Corner

This activity has expired. CME/CE credit is no longer available and the following content may not be available or may not be up-to-date. For a list of current activities that offer CME/CE credit, click here.

Program Detail

Release Date: April-29-11
Credit Expiration Date: April-29-12

Faculty

Joseph L. Blackshear, MD
Professor of Medicine
Department of Cardiology
Mayo Clinic
Jacksonville, FL

Credit Hours

1

Medium

Online Presentation

Program Description

THIS PROGRAM WAS ORIGINALLY PRESENTED AS A LIVE GRAND ROUNDS SERIES BEGINNING ON OCTOBER 28, 2010. IF YOU RECEIVED CREDIT FOR PARTICIPATING IN ONE OF THE LIVE ACTIVITIES, YOU ARE NOT ELIGIBLE TO RECEIVE CREDIT FOR THIS ONLINE RELEASE.

Approximately 2.2 million people in the United States have been diagnosed with atrial fibrillation (AF), the most common cardiac arrhythmia. Hospitalizations for AF have increased considerably in recent years, and the risk of stroke in these patients is substantial: patients with AF have a five-fold increased risk for stroke, and the condition accounts for 25% of all strokes in older adults. Because stroke is the leading cause of long-term disability and the third leading cause of death in the United States, the National Stroke Association emphasizes the importance of stroke prevention in these patients.

Long-term anticoagulation is recommended for all AF patients who have risk factors for thromboembolism. Many patients with AF receive inadequate risk assessment, however, and anticoagulation therapy is often not initiated or optimized. Hospital-based clinicians play an important role in ensuring that AF patients receive appropriate screening and treatment to prevent stroke. This activity seeks to enhance clinicians' abilities to determine when the risk for stroke exceeds the risk for anticoagulation-associated bleeding, to identify optimal anticoagulant agents and maintain the ideal therapeutic range on a case-by-case basis, and to ensure continuity of care for their patients. Emerging anticoagulants and their unique characteristics will also be discussed. Because of the serious and immediate consequences of strokes, effective preventive treatment is of the utmost importance to reduce disability and improve survival in patients with AF.

Program Developer/Facilitator

Jointly Provided by the University of California, Irvine School of Medicine and
MCM Education

Target Audience

This enduring activity has been designed for hospital-based clinicians involved in the care of patients with atrial fibrillation, including cardiologists, hospitalists, internists, physician assistants, and nurses.

Learning Objectives

Upon completion of this educational activity, the participant should be able to:

  1. Assess when the risk for stroke in patients with atrial fibrillation exceeds the risk for anticoagulation-associated bleeding.
  2. Identify the optimal anticoagulant strategy for an individual patient with atrial fibrillation based on a comprehensive risk/benefit assessment.
  3. Review the pharmacology associated with current and emerging anticoagulant agents.
  4. Summarize how new and emerging anticoagulant agents ought to be utilized for the prevention of stroke in patients with atrial fibrillation.

Disclosures

It is the policy of the University of California, Irvine School of Medicine, the University of California CME Consortium, and AKH Inc. to ensure balance, independence, objectivity and scientific rigor in all CME activities. Full disclosure of conflict resolution can be found below.

The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by UCI and AKH Inc. prior to accreditation of the activity. UCI, AKH Inc., and Medical Communications Media planners and reviewers have no relevant financial relationships to disclose.

This educational activity may contain discussion of published and/or investigational uses of pharmacologic agents. Some uses may not have been approved by the FDA. The faculty have agreed to disclose discussion of off-label use during their presentations. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views of the University of California, Irvine School of Medicine, AKH Inc., or Medical Communications Media.

Joseph L. Blackshear, MD indicates that he has no actual or potential conflict of interest to this program or presentation.

Credit Statements

Physician Continuing Medical Education:
Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the University of California, Irvine School of Medicine and Medical Communications Media. The University of California, Irvine School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
The University of California, Irvine School of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Credit is awarded to participants who listen to the presentation and provide the requested roster information and post-test responses. There is no fee to participate and receive credit.

Nursing Continuing Education:
AKH Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s COA.

AKH designates this educational activity for 1.0 contact hour (0.1 CEU). Accreditation applies solely to educational activities and does not imply approval or endorsement of any commercial product by the ANCC-COA. AKH Inc. is a provider approved by the California Board of Registered Nursing, Provider Number CEP12070, for 1.0 contact hour.

Commercial Support Statements

Supported through an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Instructions

Minimum System Requirements: • Pentium III, 600 MHz or Equivalent Processor • 512 MB of RAM • Windows XP, Vista, or 7. Or, Mac OS X • 800x600 Monitor Resolution • 16-bit Color • 16 bit Sound Card with Speakers

  1. Please turn off all pop-up blockers to assure access to the educational activity.
  2. Click on the "Start program" icon at the bottom of this page. If you are not already registered as a user of this website, this will bring you to the login/registration page where you will be able to register as a new CMEcorner.com member or check existing registration information. When ready, click on the "Continue to Program" icon at the bottom of the screen.
  3. The activity will take approximately 60 minutes to complete.
  4. After the activity has finished, click on the "Post-test" button.
  5. Instructions for completing and submitting the post-test and evaluation are provided on the post-test screen. A credit statement/certificate will be awarded for a score of 70% or better and may be printed immediately after passing the post-test.

Certificate Fee

$0.00

By clicking START PROGRAM I acknowledge that I have read the CME/CE information above.

Main Menu
EDITOR'S PICKS